Global Anxiety Disorders and Depression Treatment Market Analysis, Drivers, Restraints, Opportunities, Trends, and Growth Forecast to 2027

MarketResearch.biz, in its upcoming report titled, “Global Anxiety Disorders and Depression Treatment Market Trends, Applications, Analysis, Growth, and Forecast to 2027”, offers in-depth insights, revenue details, and other vital information regarding the global anxiety disorders and depression treatment market and the various trends, drivers, restraints, opportunities, and threats in the target market till 2027. The report also offers insightful and detailed information regarding the various key players operating in the global anxiety disorders and depression treatment market, and their financials, apart from strategies, acquisitions & mergers, and market footprint. The global anxiety disorders and depression treatment market was valued at US$ XX.X billion in 2015, and is expected show steady growth due to high prevalence of anxiety disorders and depression worldwide. The global anxiety disorders and depression treatment market report has been segmented on the basis of product, and region.

Request Covid - 19 Impact

Anxiety disorders and depression are different, but people with depression often experience symptoms similar to those of anxiety disorder, such as nervousness, irritability, and problems sleeping and concentrating. Person with anxiety disorder does not go away and can get worse over time, this feeling can interfere in daily activities such as job performance, school work and relationship. Depression is common but serious mood disorder. It causes symptoms that affect how you feel, think, and handle daily activities, such as sleeping, eating or working. To diagnosed with depression, the symptom must be present for at least two weeks.

Major factor driving growth of global anxiety disorders and depression treatment market is increasing prevalence of depression and anxiety disorders. Apart from this, rising geriatric population and increasing demand for antidepressants due to minimum side effects related to these drugs, and growing awareness among consumers are factors contributing towards growth of global anxiety disorders and depression treatment market.

However, introduction of generic variants on a large scale, patent expiration of major antidepressant drugs and weak pipeline of novel drugs, are major factors restraining the global anxiety disorders and depression treatment market. Besides challenges faced by global anxiety disorders and depression treatment market is drug resistant mental disorder, which means causing depressed patient to be noncompliant in their treatment, and the effect of certain substances can worsen the effects of depression.

North America holds largest market share for anxiety disorders and depression treatment drugs associated to presence of large patient population suffering from various types of anxiety disorders and depression, followed by Asia Pacific with high prevalence of psychiatric disorder.

Global anxiety disorders and depression treatment market segmentation by drugs:

• Serotonin reuptake inhibitors
• Tricyclic antidepressants
• Serotonin-norepinephrine reuptake inhibitors
• Tetracyclic antidepressants
• Monoamine oxidase inhibitors
• Benzodiazepines
• Atypical antipsychotics
• Anticonvulsants
• Beta blockers

Global anxiety disorders and depression treatment market segmentation by indication:

• Major depressive disorder
• Obsessive- compulsive disorder
• Phobias
• Traumatic stress disease

Global anxiety disorders and depression treatment market segmentation by region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa.

• AstraZeneca PLC
• Eli Lilly and Company
• Forest Laboratories, Inc.
• GlaxoSmithKline plc
• Lundbeck A/S
• Johnson & Johnson,
• Merck & Company, Inc.
• Pfizer, Inc.
• Sanofi- Aventis